1. Home
  2. DHF vs LRMR Comparison

DHF vs LRMR Comparison

Compare DHF & LRMR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • DHF
  • LRMR
  • Stock Information
  • Founded
  • DHF 1998
  • LRMR N/A
  • Country
  • DHF United States
  • LRMR United States
  • Employees
  • DHF N/A
  • LRMR N/A
  • Industry
  • DHF Finance Companies
  • LRMR Biotechnology: Pharmaceutical Preparations
  • Sector
  • DHF Finance
  • LRMR Health Care
  • Exchange
  • DHF Nasdaq
  • LRMR Nasdaq
  • Market Cap
  • DHF 172.4M
  • LRMR 183.8M
  • IPO Year
  • DHF N/A
  • LRMR N/A
  • Fundamental
  • Price
  • DHF $2.46
  • LRMR $2.24
  • Analyst Decision
  • DHF
  • LRMR Strong Buy
  • Analyst Count
  • DHF 0
  • LRMR 9
  • Target Price
  • DHF N/A
  • LRMR $19.00
  • AVG Volume (30 Days)
  • DHF 451.1K
  • LRMR 1.4M
  • Earning Date
  • DHF 01-01-0001
  • LRMR 04-30-2025
  • Dividend Yield
  • DHF 7.65%
  • LRMR N/A
  • EPS Growth
  • DHF N/A
  • LRMR N/A
  • EPS
  • DHF N/A
  • LRMR N/A
  • Revenue
  • DHF N/A
  • LRMR N/A
  • Revenue This Year
  • DHF N/A
  • LRMR N/A
  • Revenue Next Year
  • DHF N/A
  • LRMR N/A
  • P/E Ratio
  • DHF N/A
  • LRMR N/A
  • Revenue Growth
  • DHF N/A
  • LRMR N/A
  • 52 Week Low
  • DHF $2.06
  • LRMR $1.61
  • 52 Week High
  • DHF $2.39
  • LRMR $11.20
  • Technical
  • Relative Strength Index (RSI)
  • DHF 51.86
  • LRMR 47.46
  • Support Level
  • DHF $2.45
  • LRMR $2.03
  • Resistance Level
  • DHF $2.50
  • LRMR $3.07
  • Average True Range (ATR)
  • DHF 0.03
  • LRMR 0.30
  • MACD
  • DHF 0.01
  • LRMR 0.01
  • Stochastic Oscillator
  • DHF 69.23
  • LRMR 31.12

About DHF BNY Mellon High Yield Strategies Fund

BNY Mellon High Yield Strategies Fund is a diversified, closed-end management investment company. The fund's primary investment objective is to seek high current income and its secondary objective is capital appreciation. It invests predominantly in fixed-income securities of below-investment-grade credit quality.

About LRMR Larimar Therapeutics Inc.

Larimar Therapeutics Inc is a clinical-stage biotechnology company focused on developing treatments for patients suffering from complex rare diseases using novel cell-penetrating peptide technology platform. Its lead product candidate, CTI-1601, is a subcutaneously administered, recombinant fusion protein intended to deliver human frataxin (FXN) an essential protein, to the mitochondria of patients with Friedreich's ataxia.

Share on Social Networks: